Cargando…

Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

BACKGROUND: Correlations between development of hand–foot syndrome (HFS) and efficacy in patients receiving capecitabine (CAP)-containing therapy are reported in the literature. We explored the relationship between HFS and efficacy in patients receiving CAP plus bevacizumab (BEV) in the TURANDOT ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zielinski, Christoph, Lang, Istvan, Beslija, Semir, Kahan, Zsuzsanna, Inbar, Moshe J, Stemmer, Salomon M, Anghel, Rodica, Vrbanec, Damir, Messinger, Diethelm, Brodowicz, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815806/ https://www.ncbi.nlm.nih.gov/pubmed/26657657 http://dx.doi.org/10.1038/bjc.2015.419

Ejemplares similares

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses
por: Brodowicz, T, et al.
Publicado: (2014)

Targeting HER2 expression in cancer: New drugs and new indications
por: Vranić, Semir, et al.
Publicado: (2021)

Managing an oncology clinic during the COVID-19 pandemic—how we did it in Sarajevo?
por: Beslija, Semir
Publicado: (2020)

Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis
por: Hu, Yiyi, et al.
Publicado: (2023)

HAND-FOOT SYNDROME DUE TO CAPECITABINE
por: Surjushe, Amar, et al.
Publicado: (2009)

HAND-FOOT SYNDROME DUE TO CAPECITABINE
por: Surjushe, Amar, et al.
Publicado: (2008)

Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology
por: Kurbel, Sven, et al.
Publicado: (2017)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
por: Dyar, Stephen, et al.
Publicado: (2011)

The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
por: Amit, Limor, et al.
Publicado: (2013)

Correction: The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
por: Amit, Limor, et al.
Publicado: (2013)

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
por: Javle, M, et al.
Publicado: (2009)

Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2011)

Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
por: Molina-Garrido, M J, et al.
Publicado: (2011)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
por: Hatano, Akihiko, et al.
Publicado: (2023)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Scleroderma in a Patient on Capecitabine: Is this a Variant of Hand-Foot Syndrome?
por: Saif, Muhammad W, et al.
Publicado: (2016)

Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity?
por: Caprez, Jennifer, et al.
Publicado: (2018)

Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
por: Prager, Gerald W, et al.
Publicado: (2014)

Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
por: García-Alfonso, P, et al.
Publicado: (2010)

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
por: Hsu, C-H, et al.
Publicado: (2010)

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
por: Garcia-Alfonso, Pilar, et al.
Publicado: (2015)

Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer
por: García, Margarita, et al.
Publicado: (2015)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case Report
por: Arias Ron, David, et al.
Publicado: (2020)

Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries
por: Dimitrova, Maria, et al.
Publicado: (2020)

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
por: Saura, Cristina, et al.
Publicado: (2020)

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial
por: Thallinger, Christiane, et al.
Publicado: (2016)

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers
por: Miletić, Dragana, et al.
Publicado: (2023)

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
por: Buchler, Tomas, et al.
Publicado: (2014)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

A Case of Long Partial Response to Combination Therapy of Bevacizumab and Capecitabine for Liver Metastases of Rectal Cancer
por: Kawasaki, Atsushi, et al.
Publicado: (2011)

Bevacizumab Combined With Oxaliplatin/Capecitabine in Patient With Refractory and Recurrent Mucinous Adenocarcinoma of the Appendix: A Case Report
por: Liu, Wenzhi, et al.
Publicado: (2019)

Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS‐mutant metastatic colorectal cancer
por: Huang, Weizhen, et al.
Publicado: (2022)

Generalised Lichenoid Drug Eruption Accompanied by Hand-foot Syndrome Due to Capecitabine
por: Tamer, Funda, et al.
Publicado: (2018)

Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient
por: Whorton, Allison E, et al.
Publicado: (2022)

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
por: Rochlitz, Christoph, et al.
Publicado: (2016)

Bevacizumab in the treatment of HER2-negative breast cancer
por: Lorusso, Vito
Publicado: (2008)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h7t3kge90os410dl22738an8n2